In vitro activities of faropenem against 579 strains of anaerobic bacteria

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 11, 2002, Pages 3669-3675

  Wexler, Hannah M ^a   Molitoris, Denise ^a   St John, Shahera ^a   Vu, Ann ^a   Read, Erik K ^a   Finegold, Sydney M ^a  

^a Wadsworth Anaerobe Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAMASE; CEFOXITIN; CLINDAMYCIN; DNA POLYMERASE; FROPENEM; IMIPENEM; METRONIDAZOLE; PENEM DERIVATIVE;

ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEROIDES; BACTEROIDES FRAGILIS; BILOPHILA WADSWORTHIA; CAMPYLOBACTER; CLOSTRIDIUM DIFFICILE; FUSOBACTERIUM NUCLEATUM; FUSOBACTERIUM VARIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PEPTOSTREPTOCOCCUS; POLYMERASE CHAIN REACTION; PORPHYROMONAS; PREVOTELLA; PRIORITY JOURNAL; STRAIN DIFFERENCE;

ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; BACTERIAL PROTEINS; BETA-LACTAMASES; BETA-LACTAMS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; LACTAMS; MICROBIAL SENSITIVITY TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0036838243     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.11.3669-3675.2002     Document Type: Article

References (19)

1. Bandoh, K., K. Ueno, K. Watanabe, and N. Kato. 1993. Susceptibility patterns and resistance to imipenem in the Bacteroides fragilis group species in Japan: a 4-year study. Clin. Infect. Dis. 16(Suppl. 4):S382-S386.
2. Bennion, R. S., E. J. Baron, J. E. Thompson, Jr., J. Downes, P. Summanen, D. A. Talan, and S. M. Finegold. 1990. The bacteriology of gangrenous and perforated appendicitis - revisited. Ann. Surg. 211:165-171.
3. Edwards, R., and D. Greenwood. 1996. Mechanisms responsible for reduced susceptibility to imipenem in Bacteroides fragilis. J. Antimicrob. Chemother. 38:941-951.
4. Edwards, R., and P. N. Read. 2000. Expression of the carbapenemase gene (cfiA) in Bacteroides fragilis. J. Antimicrob. Chemother. 46:1009-1012.
5. Jousimies-Somer, H., P. Summanen, D. M. Citron, E. J. Baron, H. M. Wexler, and S. M. Finegold. 2002. Wadsworth-KTL anaerobic bacteriology manual. Star Publishing Company, Belmont, Calif.
6. National Committee for Clinical Laboratory Standards. 2001. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 5th ed. Approved standard M11-A5. NCCLS, Wayne, Pa.
7. Nikaido, H. 2001. Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria. Semin. Cell Dev. Biol. 12:215-223.
8. Ochs, M. M., M. Bains, and R. E. Hancock. 2000. Role of putative loops 2 and 3 in imipenem passage through the specific porin OprD of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:1983-1985.
9. Perez, F. J., C. Gimeno, D. Navarro, and J. Garcia-de-Lomas. 1996. Meropenem permeation through the outer membrane of Pseudomonas aeruginosa can involve pathways other than the OprD porin channel. Chemotherapy 42:210-214.
10. Podglajen, I., J. Breuil, and E. Collatz. 1994. Insertion of a novel DNA sequence, IS1186, upstream of the silent carbapenemase gene cfiA, promotes expression of carbapenem resistance in clinical isolates of Bacteroides fragilis. Mol. Microbiol. 12:105-114.
11. Podglajen, I., J. Breuil, A. Rohaut, C. Monsempes, and E. Collatz. 2001. Multiple mobile promoter regions for the rare carbapenem resistance gene of Bacteroides fragilis. J. Bacteriol. 183:3531-3535.
12. Rasmussen, B. A., K. Bush, D. Keeney, Y. Yang, R. Hare, C. O'Gara, and A. A. Medeiros. 1996. Characterization of IMI-1 β-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae. Antimicrob. Agents Chemother. 40:2080-2086.
13. Rasmussen, B. A., and E. Kovacs. 1993. Cloning and identification of a two-component signal-transducing regulatory system from Bacteroides fragilis. Mol. Microbiol. 7:765-776.
14. Rylander, M., C. E. Nord, and S. R. Norrby. 1989. Comparative in vitro activity of the new oral penem ALP-201 against aerobic and anaerobic bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 8:919-924.
15. Spangler, S. K., M. R. Jacobs, and P. C. Appelbaum. 1994. Activity of WY-49605 compared with those of amoxicillin, amoxicillin-clavulanate, imipenem, ciprofloxacin, cefaclor, cefpodoxime, cefuroxime, clindamycin, and metronidazole against 384 anaerobic bacteria. Antimicrob. Agents Chemother. 38:2599-2604.
16. Thompson, J. S., and M. H. Malamy. 1990. Sequencing the gene for an imipenem-cefoxitin-hydrolyzing enzyme (CfiA) from Bacteroides fragilis TAL2480 reveals strong similarity between CfiA and Bacillus cereus β-lactamase II. J. Bacteriol. 172:2584-2593.
17. Wexler, H. M., D. Reeves, P. Summanen, E. Molitoris, M. McTeague, J. Duncan, K. H. Wilson, and S. M. Finegold. 1996. Sutterella wadsworthensis gen. nov., sp. nov., bile-resistant microaerophilic Campylobacter gracilis-like clinical isolates. Int. J. Syst. Bacteriol. 46:252-258.
18. Woodcock, J. M., J. M. Andrews, N. P. Brenwald, J. P. Ashby, and R. Wise. 1997. The in-vitro activity of faropenem, a novel oral penem. J. Antimicrob. Chemother. 39:35-43.
19. Yamazoe, K., N. Kato, H. Kato, K. Tanaka, Y. Katagiri, and K. Watanabe. 1999. Distribution of the cfiA gene among Bacteroides fragilis strains in Japan and relatedness of cfiA to imipenem resistance. Antimicrob. Agents Chemother. 43:2808-2810.